Hypercalcaemia: assessment and emergency treatment

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Calcium symptoms depend on concentration, speed of rise, age and comorbidity. Polyuria, thirst, constipation, nausea, cognitive change, depression, proximal weakness, kidney stones and shortened QT may appear, but chronic mild primary hyperparathyroidism is often found incidentally. Confirm the result, review albumin and renal function, and inspect medicines and supplements including thiazides, lithium, calcium antacids, vitamin D and vitamin A. Take PTH at the same time as calcium before antiresorptive therapy when possible. A non-suppressed PTH supports primary or tertiary hyperparathyroidism, lithium effect or familial hypocalciuric hypercalcaemia; urinary calcium assessment helps distinguish the inherited low-excretion phenotype but is distorted by CKD, thiazides and vitamin D deficiency. Suppressed PTH directs attention to malignancy, myeloma, vitamin D-mediated disease, thyrotoxicosis and other less common causes.

Acute care prioritises volume and organ protection while the cause pathway runs concurrently. The Society for Endocrinology recommends intravenous 0.9% sodium chloride, commonly several litres over the first day in a suitable adult, but older people, heart failure and kidney disease need individual rates, reassessment and possible dialysis input. If calcium remains severely raised, an intravenous bisphosphonate is usually considered, with product-specific renal adjustment and awareness that nadir is delayed. Calcitonin may bridge selected life-threatening cases, while glucocorticoids help particular vitamin D-mediated mechanisms rather than undifferentiated hypercalcaemia. Dialysis is considered when severe renal failure, fluid intolerance or refractory life-threatening disease limits standard care. After stabilisation, cure or control the driver: parathyroidectomy for eligible primary disease, cancer therapy for malignant disease, or withdrawal of a causal agent where safe.

Key points

Verify an unexpected total calcium using albumin adjustment or ionised calcium when protein or acid-base disturbance makes total calcium unreliable.
The first mechanistic branch is PTH: hypercalcaemia should suppress it, so a high or inappropriately normal PTH indicates PTH-dependent disease.
Primary hyperparathyroidism and malignancy cause most clinically important hypercalcaemia, but medicines, granulomatous disease, thyrotoxicosis, immobility and vitamin excess matter.
PTH-independent hypercalcaemia with weight loss, bone pain, anaemia, kidney impairment or a known cancer requires an urgent malignancy-focused pathway.
Volume depletion both results from hypercalcaemia and reduces renal calcium excretion; careful isotonic saline is the foundation of acute treatment.
Loop diuretics do not routinely lower calcium and should be reserved for fluid overload after adequate volume replacement, not used to create forced diuresis.
Intravenous bisphosphonates act over days and require renal and cause review; calcitonin has a rapid but temporary role through specialist acute protocols.
Do not use bisphosphonates merely to chronically lower calcium in primary hyperparathyroidism; definitive parathyroid surgery and fracture treatment are separate decisions.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

PTH-dependent disease

Primary or tertiary hyperparathyroidism, lithium effect and familial low urinary calcium states keep PTH inappropriately unsuppressed despite confirmed hypercalcaemia.

Malignancy-related calcium release

Tumour mediators, bone destruction or altered vitamin D metabolism can raise calcium rapidly while suppressing native PTH.

Medicine and vitamin-related causes

Thiazides, lithium, calcium products, vitamin D or vitamin A exposure can cause or amplify an abnormal calcium result.

Other systemic drivers

Granulomatous disease, thyrotoxicosis, immobility and severe dehydration alter calcium entry, bone release or kidney clearance when supported by the history and examination.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Extracellular calcium rises
Increased bone resorption, intestinal absorption, renal retention or a combination raises ionised calcium above the range normally constrained by PTH feedback.
2
Renal water loss develops
High calcium impairs urinary concentration and promotes natriuresis, producing polyuria, volume depletion and reduced kidney calcium clearance.
3
Neurological and cardiac function changes
Membrane and conduction effects cause weakness, cognitive slowing, shortened cardiac repolarisation and, in severe or rapid disease, delirium or arrhythmia.
4
A self-amplifying cycle forms
Vomiting and renal water loss worsen dehydration and kidney function, which further limits calcium excretion and accelerates toxicity.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Neurological toxicity

New confusion, lethargy, delirium, weakness, seizure or coma with a rapid calcium rise indicates severe physiological effect and warrants monitored acute correction.

Renal water loss

Thirst, polyuria, dehydration, rising creatinine and nephrolithiasis reflect impaired concentration and calcium-related kidney injury, often amplifying the calcium rise.

PTH-dependent pattern

Raised or inappropriately non-suppressed PTH during confirmed hypercalcaemia suggests primary or tertiary hyperparathyroidism, lithium effect or familial hypocalciuric hypercalcaemia.

Malignancy signal

Rapid onset, weight loss, night pain, anaemia, renal impairment, suppressed PTH, known cancer or very high calcium increases urgency for malignancy and myeloma evaluation.

Cardiac compromise

Shortened QT, bradyarrhythmia or other rhythm disturbance may occur; concurrent potassium, magnesium, dehydration and digoxin exposure can magnify risk.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Repeat albumin-adjusted or ionised calciumFirst step
Why
Confirm true hypercalcaemia and establish severity when albumin or critical illness affects total calcium.
Interpretation and limitations
Persistent elevation supports a biological disorder. Ionised calcium is most useful when protein binding or acid-base state makes adjusted values uncertain.
02
Concurrent PTH
Why
Divide causes into PTH-dependent and appropriately PTH-suppressed pathways.
Interpretation and limitations
A non-suppressed value is inappropriate during hypercalcaemia and points towards parathyroid or lithium-related disease; a low value triggers malignancy, vitamin D and other investigation.
03
Urea, electrolytes, eGFR, phosphate and magnesium
Why
Assess organ injury, volume depletion and constraints on fluid or antiresorptive therapy.
Interpretation and limitations
Acute kidney injury increases severity and medicine risk; phosphate and magnesium contribute to mechanistic interpretation and safe correction.
04
ECG
Why
Detect calcium-related repolarisation change and rhythm instability before and during treatment.
Interpretation and limitations
A shortened QT or arrhythmia strengthens the need for monitored care; a normal tracing does not make marked biochemical elevation safe.
05
Urine calcium assessment
Why
Help distinguish primary hyperparathyroidism from familial hypocalciuric hypercalcaemia in stable PTH-dependent disease.
Interpretation and limitations
Low clearance may support FHH but is not definitive when CKD, thiazides, low calcium intake or vitamin D deficiency alter excretion; seek specialist interpretation.
06
Malignancy-directed testing
Why
Identify cancer, myeloma or a humoral mechanism when PTH is suppressed or red flags are present.
Interpretation and limitations
Select blood count, protein electrophoresis and imaging from the phenotype; PTH-related peptide and vitamin D metabolites are specialist tests rather than routine panels.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Albumin-related total calcium rise

High albumin or protein disturbance can raise total calcium without equivalent ionised hypercalcaemia; adjusted or ionised measurement clarifies genuine exposure.

Primary hyperparathyroidism

A raised or inappropriately non-suppressed PTH during confirmed hypercalcaemia supports parathyroid-driven disease rather than most malignant causes.

Familial hypocalciuric hypercalcaemia

Lifelong mild hypercalcaemia, family history and relatively low urinary calcium suggest this inherited phenotype, although kidney disease and medicines confound excretion.

Malignancy

Suppressed PTH with rapid onset, weight loss, bone pain, anaemia or known cancer directs urgent investigation toward tumour-related mechanisms.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01ResuscitateCorrect severe physiologyFirst stepMarked calcium elevation accompanies symptoms, dehydration, renal injury or ECG concern.

1Assess ABCDE, ECG, fluid balance and cardiac-renal comorbidity, repeat calcium and obtain PTH and renal bloods without postponing treatment.
2Give monitored intravenous 0.9% sodium chloride to restore euvolaemia, adjusting rate to response and seeking renal or critical-care help when fluid tolerance is limited.
3If severe hypercalcaemia persists, choose an antiresorptive or rapid bridging treatment with specialist input, renal safeguards and planned serial calcium review.

02LocaliseUse the PTH branchConfirmed hypercalcaemia is stable enough for mechanistic investigation.

1Review medicines, supplements, previous calcium, kidney stones, fracture, cancer symptoms and family history and interpret simultaneous calcium and PTH.
2For non-suppressed PTH, assess vitamin D, renal function and urinary calcium before parathyroid referral; for suppressed PTH, pursue malignancy and vitamin D-mediated causes proportionately.
3Avoid localisation scans until biochemical primary hyperparathyroidism is established, because imaging plans surgery rather than making the diagnosis.

03DefinitivePrevent recurrence after stabilisationDefinitiveCalcium and organ function improve but the underlying cause remains active.

1Refer primary hyperparathyroidism according to NICE surgical criteria and evaluate renal and skeletal end-organ disease.
2Coordinate oncology, haematology, respiratory or inflammatory care for PTH-independent disease and remove causal medicines only after benefit-risk review.
3Provide hydration, medicine and symptom safety-netting, arrange calcium and renal follow-up, and specify who will review delayed antiresorptive hypocalcaemia.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Restores glomerular filtration and renal calcium excretion while correcting the common hypercalcaemic volume deficit.

Intravenous 0.9% sodium chloride

Use the Society for Endocrinology and local resuscitation regimen, titrating the initial and ongoing rate to blood pressure, urine output, sodium, renal function and cardiac reserve rather than prescribing a fixed volume for every adult.

Pulmonary oedema can occur in older adults or cardiac and renal failure. Reassess frequently; loop diuretic is not routine calcium therapy and is used only for fluid overload after rehydration.

Inhibits osteoclast-mediated calcium release, particularly in severe persistent or malignancy-related hypercalcaemia, with effect developing over several days.

Intravenous bisphosphonate

After adequate rehydration, select the antiresorptive for the cause and renal function. For adult tumour-induced hypercalcaemia with albumin-corrected calcium at least 3.0 mmol/L, the current zoledronic acid SmPC recommends a single 4 mg intravenous infusion over no less than 15 minutes; use the specific BNF, SmPC or specialist protocol for other causes or products.

Check renal function, calcium and vitamin D context; acute-phase reactions, kidney injury and delayed hypocalcaemia occur. Obtain dental and jaw-risk advice when repeated cancer or bone courses are anticipated.

Reduces osteoclast activity and renal calcium reabsorption within hours, bridging the slower onset of antiresorptive treatment.

Calcitonin

Use a weight-based short specialist regimen from the local acute hypercalcaemia protocol when a rapid temporary calcium reduction is needed while definitive treatment takes effect.

Tachyphylaxis limits benefit after the first days, nausea and hypersensitivity occur, and availability or local use varies; it does not replace hydration or cause treatment.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Acute kidney injury

Polyuria, vomiting and calcium-related renal effects cause volume depletion and declining filtration, which further reduces calcium clearance and worsens toxicity.

Neurological deterioration

A rapid or severe calcium rise can progress from lethargy and confusion to delirium, seizure and coma, indicating a medical emergency.

Cardiac arrhythmia

Shortened repolarisation and interacting potassium, magnesium, dehydration or digoxin effects can produce clinically important conduction disturbance.

Stone and skeletal disease

Persistent PTH-driven hypercalcaemia can cause nephrolithiasis and loss of bone strength even when acute neurological symptoms are absent.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

During resuscitation, chart observations, urine output, net fluid balance, weight, oxygenation and signs of pulmonary oedema.
Repeat calcium, renal function, potassium, magnesium and phosphate at a frequency matched to severity and medicine onset.
After bisphosphonate treatment, anticipate the delayed nadir and monitor for hypocalcaemia, especially with vitamin D deficiency or high bone turnover.
For primary hyperparathyroidism awaiting or not undergoing surgery, follow NICE calcium, renal and skeletal surveillance rather than symptoms alone.
Escalate recurrent vomiting, confusion, reduced urine, severe thirst or weakness because relapse can precede the planned clinic appointment.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

PTH normality can be abnormal

A mid-range PTH is inappropriate when calcium is high because normal physiology should suppress it. Context, not the printed flag, determines the branch.

Dehydration creates a loop

Hypercalcaemia impairs urinary concentration, causing water loss; falling filtration then reduces calcium excretion and amplifies the original disturbance.

Image after chemistry

A parathyroid scan cannot distinguish primary hyperparathyroidism from FHH. It localises a gland only after biochemical diagnosis and a surgical decision.

Bisphosphonate effect is delayed

The calcium may continue rising before osteoclast inhibition takes effect. Early response must be judged through hydration, symptoms and serial measurements rather than abandoning treatment prematurely.

Pain may have two causes

In malignancy, skeletal pain can reflect metastasis while hypercalcaemia drives weakness and confusion. Correcting calcium does not complete oncological assessment.

11Common pitfallsFrequent interpretation and management errors.

01
Using total calcium uncritically in severe hypoalbuminaemia or major acid-base disturbance.
02
Calling a PTH within its laboratory range reassuring when it should be suppressed by hypercalcaemia.
03
Ordering parathyroid imaging before confirming PTH-dependent disease and considering FHH.
04
Forcing diuresis with loop diuretic before restoring intravascular volume.
05
Giving a renally cleared bisphosphonate without checking kidney function and the product protocol.
06
Discharging after the number falls without assigning definitive cause follow-up and delayed calcium monitoring.